Key result
Soluble platelet-activation markers including sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 were significantly elevated in patients with coronary artery disease versus healthy subjects.
Why the study?
Given the role of platelets in CAD, assessing soluble platelet-activation markers may be useful to improve thrombotic risk stratification.
Are soluble platelet-activation markers elevated in patients with coronary artery disease compared to healthy subjects?
Meta-Analysis
Are soluble platelet-activation markers elevated in patients with coronary artery disease compared to healthy subjects?
Answers are grounded in this paper and cite their sources.
Soluble platelet-activation markers including sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 are significantly elevated in patients with CAD, particularly in ACS, suggesting potential utility for thrombotic risk stratification.
BACKGROUND: Given the role of platelets in coronary artery disease (CAD), assessment of a soluble platelet-activation marker may be useful to improve thrombotic risk stratification. OBJECTIVES: This study aimed to perform a meta-analysis investigating the association between levels of 14 such markers associated with CAD. When possible, patients with CAD were stratified into acute coronary syndrome (ACS) and chronic coronary disease. Standardized mean difference (SMD) was calculated. RESULTS: Due to heterogeneity in the assessed studies, meta-analysis was performed for sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, SCUBE1, and TSP-1. All markers but TSP-1 were significantly elevated in patients with CAD compared with HSs. Differences in sCD40L and SCUBE1 were statistically significant only when studies that assessed plasma were combined with those that assessed serum. When compared with HSs, the differences were bigger in patients with ACS than patients with chronic coronary disease for MMP-9 (SMD, 2.49 vs 0.49), PF4 (SMD, 2.01 vs 0.96), and sP-selectin (SMD, 1.81 vs 0.63). Publication bias was identified for sCD40L and, in ACS, for sP-selectin and PF4. CONCLUSION: The increased levels of sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 in patients with CAD compared with HSs provide a rationale for designing new studies to address the potential of such molecules as biomarkers for thrombotic risk stratification.
No takes yet. Share an insight, caveat, or question.
Brambilla et al. (2025) conducted a meta-analysis in Coronary artery disease. Soluble platelet-activation markers vs. Healthy subjects was evaluated on Levels of soluble platelet-activation markers. Soluble platelet-activation markers including sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 were significantly elevated in patients with coronary artery disease versus healthy subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: